

Article

Not peer-reviewed version

In situ Aqueous Spice Extract Based Antifungal Lock Strategy for Salvage of *Candida albicans* Biofilm Gels in Foley's Catheter

[Bindu Sadanandan](#)*, [Vaniyamparambath Vijayalakshmi](#), [Kalidas Shetty](#), Adithya Rathish, [Harshala Shivkumar](#), Malavika Gundreddy, Nikhil Kumar Kagganti Narendra, Nethra Machamada Devaiah

Posted Date: 28 November 2024

doi: 10.20944/preprints202411.2197.v1

Keywords: Antifungal Lock Therapy; In Situ, Foley's Catheter; Gel; Biofilm; Spice Extract; *Candida albicans*



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

In Situ Aqueous Spice Extract Based Antifungal Lock Strategy for Salvage of *Candida albicans* Biofilm Gels in Foley's Catheter

Bindu Sadanandan ^{1,*}, Vaniyamparambath Vijayalakshmi ¹, Kalidas Shetty ², Adithya Rathish ¹, Harshala Shivkumar ¹, Malavika Gundreddy ¹, Nikhil Kumar Kagganti Narendra ¹ and Nethra Machamada Devaiah ¹

¹ Department of Biotechnology, M S Ramaiah Institute of Technology, Bengaluru 560054, Karnataka, India

² Department of Plant Sciences, North Dakota State University, Fargo, ND 58105, USA

* Correspondence: bindu@msrit.edu

Abstract: *Candida* forms gel like biofilm in the Foley's catheter causing tenacious biofouling and severe urinary tract infections (UTI). For the first time a spice extract based antifungal lock therapy (ALT) has been developed to inhibit *Candida albicans* gel matrix in Foley's catheter. Aqueous extracts of garlic, clove and Indian gooseberry were used as ALT lock solutions and tested against biofilm-forming multidrug-resistant clinical isolates of *C. albicans*. The reduction in the gel matrices formation in the catheter was confirmed by Point inoculation, MTT assay, CFU, and SEM analysis at 12 and 24 h of incubation. Garlic was effective in controlling both *C. albicans* M207 and *C. albicans* S470, however, clove and gooseberry effectively controlled the latter. As evidenced by MTT assay and CFU there was a 55 and 96% reduction in the growth of *C. albicans* at 24 h of incubation. SEM revealed a switch from the biofilm to the yeast mode and a drastic reduction in cell numbers with mostly clumped or lysed cells. The study will provide an impetus to the development of novel spice extract-based ALT, reducing selection pressure on the pathogen and lowering antimicrobial resistance. Further research in this area has potential to leverage clinical applications.

Keywords: antifungal lock therapy; *in situ*; Foley's catheter; gel; biofilm; spice extract; *Candida albicans*

1. Introduction

Centers for Disease Control and Prevention categorizes major Hospital Acquired Infections (HAI) as Central Line-Associated Bloodstream Infections (CLABSI), Catheter-Associated Urinary Tract Infections (CAUTI), Ventilator Associated Pneumonia (VAP), and Surgical Site Infections (SSI) [1]. CAUTI occurs in individuals whose urinary bladder is catheterized or will be catheterized within 48 h and can cause secondary bloodstream infections. They represent about 12-50% of overall hospitalized infections [2]. CAUTI contributes to almost 80% of the nosocomial Urinary Tract Infections (UTIs) [3]. This may be due to the fact that the catheterized patients urinary bladder is not emptied completely which serves a nidus for infection. CAUTI can be caused by bacteria or fungi [4], which either enter through the blood stream or retrograde via urethra or bladder. Though major causative of CAUTI is bacterial infection, fungi also significantly contributes especially in the hospital settings with already suffering Candidemia or immunocompromised patients. Amongst fungi *Candida* (23%) species is the most common pathogen which attributes to almost 1/4th of the cases [5,6]. These organisms form a self-produced gel matrix composed of polysaccharides, protein and DNA called biofilms. They are the fourth leading hospital-associated infection and the highest rate of morbidity and mortality in CAUTI is associated with *Candida* species [7,8], more in the ICU setting [9,10], especially *C. albicans* [11].

Candida species in the UTI have an overall prevalence rate of 11.2% with a high incidence rate of 59.7% between the age groups of 21-30 years [12]. Pregnant women have a higher rate of UTI (33%)

than married women (27%) or single women (15%). Married males exhibited an 18% prevalence of UTI than single men (7%) [13]. *Candida* associated CAUTI becomes more serious in patients when they are drug resistant. Multi drug *Candida* species are more prevalent in hospital infections. People with UTI caused by multidrug resistant *Candida* species will have to try multiple drugs which can lead to tissue and systemic toxicity, ultimately giving complicated side effects.

Candida biofilm is a gel like extracellular polysaccharide (EPS) matrix which anchors to the surface of medical devices. It can form facilitating adhesion to medical devices causing their fouling and rendering them unfit for use. EPS acts as a natural gel that binds the microbial cells together to form cell aggregates or the biofilm in order to provide protection to the microorganism against abiotic and biotic stress. The formation of biofilm is most common in urinary catheters especially Foley's catheters [14] which may lead to severe cervical canal infections [15], urinary tract infections [16], and a cause for high-risk nosocomial candiduria [17]. These biofilms are made up of microbial cells along with gel like EPS, which can vary in its thickness and percentage of composition. Infections caused by *Candida* species in the catheter lead to the removal of the infected catheter followed by antifungal therapy and then replacement with a new one [18], however in some patients it is not advisable to have the catheter removed.

ALT is used to clear the catheters off biofilms by involving a continuous infusion of antimicrobials called ALT lock solutions at high concentrations into the catheter lumen for extended periods [19]. To salvage the catheters, ALT can be applied either *ex situ/ex vivo* or *in situ/in vivo*. Some of the conventional ALT lock solutions for fungal biofouling are: fluconazole [20] caspofungin [21,22], micafungin [21,23], amphotericin B [22], ethanol [24] and silver nanoparticle [25]. The concentration of conventional lock solutions is 10x times more than that of the therapeutic range. The use of high doses of conventional antimicrobials in the *in vivo* ALT has severe side effects on the patient. It is also not very effective on multidrug resistant organisms like *C. albicans*. This calls for an alternative ALT lock solution that can prevent toxic side effects.

Spice, condiment and herb extracts like garlic [26,27], cinnamon, clove, jasmine, rosemary [28] and Indian gooseberry (amla) extracts have potential antifungal effect [29] and with no known toxicity [30]. Therefore, antifungal spice extracts have prospects as natural and ALT lock solutions in preventing biofouling of catheters and thereby mitigating fungaemia and septicaemia in affected patients. However, the effectiveness of ALT would depend on the choice, concentration and time of incubation of the antifungal agents.

In this study we have targeted the use of three spice extracts, garlic (*Allium sativum*), clove (*Syzygium aromaticum*), and Indian gooseberry (*Phyllanthus emblica*) as ALT lock solutions, in the development of an *in situ* ALT, to control the biofouling of Foley's catheter by *C. albicans* M207 and S470. Garlic contains free amino acids (1.2%), fiber (1.5%), protein (2%), organosulphur compounds (2.3%), carbohydrates (28%), and water (65%) [31]. Main constituents of organosulphur compounds include alliin (S-allyl-L-cysteine-sulfoxide), diallyl thiosulphinates, allicin (S-allyl prp-2-ene-1-sulfinothioate), ajoenes, diallyl polysulfides, diallyl sulfide, allyl propyl disulfide, diallyl trisulfide, allyl methyl trisulfide etc. The disruption of garlic releases enzymes like alliinase that converts alliin into allicin. Allicin is the main component in garlic which constitutes to 70-80% of sulphur compounds. However, allicin is highly unstable and can decompose into other stable organosulphur compounds including allyl sulfide, diallyl sulfide, triallyl sulfide, ajoenes etc [32]. The compounds in garlic are responsible for its antifungal, antibacterial, anti-oxidant, anti-cancer, and anti-inflammatory properties [33]. Clove has bioactive components such as eugenol acetate, eugenol, caryophyllene, gallic acid, ellagic acid, biflorin, kaempferol, quercetin. Clove is known for its antifungal, antibacterial, antioxidant, analgesic, anti-infective, and anti-inflammatory properties [34–36]. Indian gooseberry is a source of vitamin C (450-600mg100g⁻¹), however, other vitamins include niacin, carotene, thiamine, riboflavin [37,38]. The amino acids present are glutamic acid, proline, aspartate, alanine and lysine [39]. The phytochemicals present are gallic acid, ellagic acid, emblicanin A, emblicanin B, phyllanthin, phyllatidine, quercetin etc [40]. The compounds in gooseberry show antioxidant, anti-cancer, chemoprotective, anti-viral, immunomodulatory, anti-aging, anti-inflammatory, etc properties. The antimycotic activity of these extracts on *C. albicans* M207

and S470 was studied by point inoculation, MTT assay, colony forming unit, and SEM. Further studies in aqueous spice extract based *in situ* ALT would pave the way for its implementation in clinical practice.

2. Results

2.1. Foley's Catheter

Urinary catheters have been an important part of medical care since the invention of the Foley's Catheter (FC). A typical Foley's catheter has a capacity of 10 mL with a length of 400 mm (Figure 1). It has two channels, one called the drainage channel to discard the urine and the second inflation channel which helps to retain the catheter in the bladder [41]. The benefits of the FC also come with its innate risks. When used frequently and for prolonged periods it can become a niche for various microorganisms, especially biofilm formers that will be a perpetual source of acute to severe Urinary Tract Infections (UTIs) and other life-threatening infections.



Figure 1. Silicone Foley's catheter.

2.2. Point Inoculation

A large spreading biofilm phenotype of the *C. albicans* M207 and S470 cultures were grown in the 12 and 24 h control plates with the catheter section and as expected more growth was observed at 24 h. Both the centre and peripheral sections of the catheter when point inoculated on TSA media exhibited a similar extent of growth, indicating uniform growth of the culture throughout the catheter.

Point inoculation of garlic extract treated section of catheter with *C. albicans* M207 showed substantial inhibition in the growth along with a drastic regression of the biofilm for both 12 and 24 h of incubation (Figure 2).

Catheters with *C. albicans* S470 were treated with extracts of garlic, clove and gooseberry extracts. All the three extracts were found to be effective in controlling the biofilm at 12 and 24 h of incubation (Figure 2). However, among them, garlic was the most effective followed by clove and then gooseberry.




Figure 2. Panel 1: Point inoculation of the catheter sections at 12 h of incubation for (a) Control, (b) Garlic, (c) Clove, and (d) Gooseberry extracts. (A) *C. albicans* M207 centre, (B) *C. albicans* M207 periphery, (C) *C. albicans* S470 centre, (D) *C. albicans* S470 periphery. Panel 2: Point inoculation of the catheter sections at 24 h of incubation for (a) Control, (b) Garlic, (c) Clove, and (d) Gooseberry extracts. (A) *C. albicans* M207 centre, (B) *C. albicans* M207 periphery, (C) *C. albicans* S470 centre, (D) *C. albicans* S470 periphery

2.3. MTT Assay

MTT assay was also performed for the centre and periphery sections of the catheters of 12 (Figure 3, Panel 1) and 24 h grown cultures (Figure 3, Panel 2) for the reconfirmation of uniform growth in the catheter. This assay also helps to directly confirm the viability and indirectly the inhibition of *C. albicans* M207 against garlic extract of *C. albicans* S470 against garlic, clove, and gooseberry extracts. Amongst these three extracts, for *C. albicans* S470 the most effective was garlic, followed by clove and gooseberry.

For 12 h of incubation, *C. albicans* M207 showed 86% viability at the centre and 89% at the periphery region when treated with garlic. However, at 24 h of incubation, on treatment the viability decreases to 71% at the centre and 72% at the periphery regions. *C. albicans* S470 at 12 h of incubation with the extracts showed a percentage viability of 75% for garlic, 92% for clove, and 96% for gooseberry at the centre, and a percentage viability of 76% for garlic, 86% for clove, and 94% for gooseberry at the periphery region. However, at 24 h of incubation, the percentage viability was only 45% for garlic, 69% for clove, and 62% for gooseberry at the centre, and at the periphery, 48% for garlic, 57% for clove, and 62% for gooseberry. The targeted extracts were found to be efficacious in inhibiting the biofilm of both the cultures in the centre as well as the peripheral regions of the catheter with the 24 h being more effective than the 12 h.

The MTT assay confirmed the antimicrobial activity of the spice extracts against the tested multidrug resistant clinical isolates of *C. albicans*.




Figure 3. Panel 1: MTT assay of centre and periphery regions of the catheter having *C. albicans* M207 and *C. albicans* S470 grown for 12 h and treated with Garlic, Gooseberry, and Clove. * $p \leq 0.05$, ** $p \leq 0.01$. Asterisk indicates significant difference with respect to the control. Panel 2: MTT assay of centre and periphery regions of catheter having *C. albicans* M207 and *C. albicans* S470 grown for 24 h and treated with Garlic, Gooseberry, and Clove. **** $p \leq 0.0001$. Asterisk indicates significant difference with respect to the control.

2.4. Colony-Forming Unit (CFU)

CFU was determined for *C. albicans* M207 with garlic extract (Figure 4: Panel 1, Table 1) and *C. albicans* S470 (Figure 4: Panel 2, Table 2) with garlic, clove and gooseberry at 12 and 24 h of incubation.

Garlic was very effective in inhibiting *C. albicans* M207 and S470 followed by clove and gooseberry for the latter.

It can be observed that 12 and 24 h of incubation for *C. albicans* M207 with garlic extract had the same % kill of 82.35% at 10^{-1} dilution. At the same dilution, for *C. albicans* S470, with inhibition with garlic was 98.42% and 96.81% for 12 and 24 h respectively. Clove and gooseberry had a better kill % at 12 h than at 24 h of incubation. Percentage kill for clove was 97.6% and 51.59% for 12 and 24 h respectively, and the percentage kill for gooseberry was 97.6% and 59.23% for 12 and 24 h respectively.

The colonies appear to be smaller and more in number at 12 h of incubation, however at 24 h the colonies appear to be bigger, and less in number. The higher dilutions of the CFU (10^{-2} , 10^{-3} , 10^{-4}) are shown in the Figure S1, Figure S2, Figure S3 and Figure S4.




Figure 4. Panel 1: CFU of (A) *C. albicans* M207 control treated with (B) garlic extract at 12 and 24 h of incubation. (a)12 h neat, (b) 12 h 10^{-1} dilution, (c) 24 h neat, (d) 24 h 10^{-1} dilution. Panel 2: CFU of (A) *C. albicans* S470 control treated with (B) garlic, (C) gooseberry, and (D) clove extracts at 12 and 24 h of incubation. (a)12 h neat, (b) 12 h 10^{-1} dilution, (c) 24 h neat, (d) 24 h 10^{-1} dilution.

Table 1. CFU results of *C. albicans* M207 treated with garlic extract at 12 and 24 h of incubation.

Dilutions	<i>C. albicans</i> M207 – CFU/mL					
	12 h			24 h		
	Control	Garlic Treated	% Kill	Control	Garlic Treated	% Kill
Neat	*Not countable	1510	-	1950	560	71.28
10 ⁻¹	1700	300	82.35	7000	1200	82.85
10 ⁻²	26000	0	100	50000	5000	90
10 ⁻³	60000	0	100	220000	10000	95.45
10 ⁻⁴	200000	0	100	1500000	0	100

*Colonies are too small and too many to be counted.

Table 2. CFU results of *C. albicans* S470 treated with garlic, clove and gooseberry extracts at 12 and 24 h of incubation.

Dilutions	12h						
	Control	Garlic Treated	% Kill	Clove Treated	% Kill	Gooseberry Treated	% Kill
Neat	*Not countable	90	-	270	-	280	-
10 ⁻¹	12700	200	98.42	300	97.63	300	97.63
10 ⁻²	2000	1000	95	1000	95	1000	95
10 ⁻³	90000	0	100	0	100	10000	88.88
10 ⁻⁴	0	0	100	0	100	0	100

*Colonies are too small and too many to be counted.

2.5. Scanning Electron Microscopy

Since the surface area exposed is less in the cross-section (Figure S5, Figure S6) of the catheter as opposed to the longitudinal section the details revealed in the SEM images of the latter were far superior to the former especially with respect to the morphology of the cells and the EPS gel. Abundant cells embedded in the thick EPS gel matrix can be observed in the control images of *C. albicans* M207 and S470 at 12 and 24 h (Figure 5) of incubation. In the images of *C. albicans* M207 treated with garlic extract for 12 h we can observe clumped and dead cells enmeshed in the almost negligent gel matrix, however, at 24 h of incubation, the patches of clumped cells have mostly reduced revealing the distorted EPS gel in the background. Likewise, the micrographs of the garlic, clove, and gooseberry treated *C. albicans* S470 for both the time durations, also revealed clumped and dead cells in the diminished EPS gel. Here too garlic was the most effective in inhibiting the pathogenic yeast. In the images of the clove and gooseberry-treated catheter sections still few cells embedded in the EPS gel are seen.

The SEM analysis confirms the effectiveness of the spice extracts against *C. albicans* M207 and S470 which was previously observed through Point inoculation, CFU and MTT assays.




Figure 5. SEM analysis of the longitudinal section of the catheter. Panel 1: Blank catheter. Panel 2: (A) *C. albicans* M207 at 12 h, (B) *C. albicans* S470 at 12 h, (C) *C. albicans* M207 at 24 h and (D) *C. albicans* S470 at 24 h. (a) Control, (b) Garlic treated, (c) Gooseberry Treated, (d) Clove treated.

3. Discussion

Biofilm and the associated pathogen infections are a major problem in implants especially in catheters and are recalcitrant to the conventional antimicrobials [42]. The major classes of conventional antifungals are azole (fluconazole, voriconazole, itraconazole etc), echinocandin (caspofungin, micafungin, anidulafungin, etc), polyene (amphoterecin B, nystatin, natamycin, etc) allylamine (terbinafine, naftifine, tonaftate, etc), and miscellaneous (griseofulvin, flucytosine, etc). Conventionally to salvage the catheter in patients antimycotics such as caspofungin, and amphotericin B, have been used in antimicrobial lock therapy [43]. For lock therapy a lock solution should have the following characteristics: High stability, low potential to resistance, cost effective, non-toxic, ability to penetrate the EPS gel, and be target specific [24]. Conventional antimicrobials such as Caspofungin and Amphotericin B have been used previously as lock solutions in inhibiting *Candida* organism [44]. Azoles such as fluconazole, and voriconazole are effective in removing *Candida* biofilms [44]. Nikkomycin Z in combination with echinocandins is reported as a good possible adjuvant in lock therapy [45]. However, in another study with the same agents, the results were found to be negative [46]. Some of the classes of antifungal agents and their effect on *Candida* is: Azoles can inhibit the ergosterol synthesis by blocking lanosterol 14 α demethylase, echinocandins affect the cell wall by blocking β -glucan synthesis, polyenes attack the plasma membrane binding to ergosterol, allylamine inhibits the squalene epoxidase which is an essential enzyme in ergosterol pathway. Griseofulvin a polyketide miscellaneous class of antifungal agent blocks mitosis by preventing synthesis of microtubule and microfilaments. Flucytosine a nucleotide analogue also classified under miscellaneous antifungals inhibits the synthesis of nucleic acid (Figure 6).

Repeated use of conventional ALT can be harmful to the body due to the high concentrations of the ALT drugs and their side effects. Previous publications have shown the effective inhibition of *Candida* species with garlic, [47] clove [28] and gooseberry extracts [48] as alternative therapies. The major component in garlic extract is allicin, gooseberry is gallic acid and clove is eugenol or ellagic acid [49]. We have also found similar results through LCMS in our previous study. In clove however, the major compound detected was ellagic acid [47]. Active principles of garlic (allicin), clove (eugenol and ellagic acid) and gooseberry (gallic acid) enter into the cells by simple diffusion. Garlic extract damages the cell wall and causes cell collapse. In its multi-mode action, it affects lipid synthesis, reduces oxygen consumption, inhibits succinate dehydrogenase in Krebs cycle and inactivates thiol peptide (glutathione) and proteins (glutathione peroxidase, glutathione reductase, coenzyme A) that act as innate antioxidants leading to oxidative stress thereby also triggering ROS generation. It can also alter gene expression involved in oxidative-reduction processes, damage mitochondria and downregulates ECE1 virulence factor that encodes candidalysin [50]. They also affect the sodium potassium pump and inactivate quorum sensing genes. The clove extract binds to ergosterol on the cells and disrupts the cell membrane. It enters into the cell and inhibit toxin production, releases intracellular components like radicals, cytochrome C, ions, protein, nucleic acid etc, affect transport of ions and ATP, leading to cell death. It is also known to inhibit adhesion and biofilm formation along with inhibiting toxin production [51,52]. The components in gooseberry extract destroy the cell wall leading to cytoplasm leakage, damage protein, DNA, RNA, and disrupt enzymatic activity. Of the components, alkaloids alter the genetic material of the microbes, phenols like ellagic acid and gallic acid control protein and lipid ratio, flavonoids inhibit RNA synthesis and tannins inhibit oxidative phosphorylation [53,54]. The antifungal activity of these active principles of garlic, gooseberry and clove depends on the quantity of the major component present, however it is difficult to identify the specific site of action as there are several interactive reactions happening simultaneously (Figure 6) [51,55,56].




Figure 6. The proposed mechanism of action of allicin, eugenol/ellagic acid, and gallic acid of garlic (pink arrow), clove (black arrow) and gooseberry (green arrow) respectively on *Candida* sp. Allicin causes cellular damage, affects sodium potassium pump, affects lipid synthesis, causes lipid peroxidation, inactivates thiol peptide (glutathione) & proteins (glutathione peroxidase, glutathione reductase, coenzyme A) that act as innate antioxidants leading to oxidative stress thereby also triggering ROS generation, damages mitochondria, reduces succinate dehydrogenase, produces ROS which in turn causes cytochrome C release, caspase activation and apoptosis, inhibition of ECE1 virulence factor/candidalysin, and inactivates quorum sensing genes. Eugenol/ellagic acid causes cellular damage, releases cytochrome C, leading to caspase activation and apoptosis, produces ROS, releases nucleic acid and proteins, inhibits ECE1 virulence factor/candidalysin, forms DNA adduct.

Gallic acid causes cellular damage leading to cytoplasmic leakage, damage to nucleic acid and proteins, and inhibits RNA synthesis. Classes of conventional antimycotics (azole, allylamine, echinocandins, polyenes, and miscellaneous class - griseofulvin, and nucleotide analogue) and their binding sites have also been depicted in the figure.

Hence, we have used these aqueous extracts as ALT lock solutions in place of first line antimycotics to inhibit biofilm buildup of multi drug resistant clinical isolates of *C. albicans* M207 and S470. CFU and MTT assay were used to monitor the cell viability and metabolic activity of the *Candida* cultures on treatment with the spice extracts [57,58]. In our earlier publication we have observed that *C. albicans* biofilm when grown on polystyrene surface has an MIC 50 of 1 mg at 12 h of incubation for aqueous garlic extract and at 24 h, persister cells further enhanced the growth of *C. albicans*. In the coculture of *C. albicans* M207 and *E. coli* until 12 h the biofilm was mostly contributed by the latter however at 24 h the former overcame the inhibitory effect of the latter and the biofilm was mostly contributed by *C. albicans* M207 [27]. However, in the present study, when garlic treated *C. albicans* M207 was grown in the Foley's catheter, even up to 24 h a significant reduction in the viability of cells was observed mostly due to the difference in the gel matrix in the lumen of silicone elastomer catheters as opposed to growth on the surface of silicone elastomer disks. In all probability the EPS gel in the catheter is still in its exponential phase and had not developed into a fully mature one [59].

As in this study, Mukherjee et al., 2009 have also observed in SEM analysis, debris and dead cells on treatment with conventional antimicrobials [60]. Ionescu et al., 2021 observed a uniform growth of biofilm in the intravascular and intraluminal FC, however observed cluster formation in the latter [14].

The whole spice extracts used in the study showed a very effective inhibition of *C. albicans* in the Foley's catheter. These extracts have multiple active principles present in them which are responsible for their antimicrobial property. However, purified active compounds alone or in combination with first line antimycotics may play a very important role as the future therapeutics for the treatment of *Candida* infected catheters *in vivo*

4. Conclusions

Though ALT has its strengths the limitations are that the success of the therapy depends on the species and the strain of pathogen involved, like in our case *C. albicans* M207 strain can only be inhibited with aqueous garlic extract (AGE) whereas *C. albicans* S470 strain with garlic, gooseberry and clove. Multiple doses may assist in eliminating *C. albicans* species in the catheter. The dose depends on the eukaryotic nature and the ergosterol availability on the species cell wall. Since no organic solvents are used in the extract preparation, it is environmentally friendly and incorporates intrinsic safety into the therapeutic preparation. As in precision medicine it is not just the pathogenic species that is to be considered but also the strain. Hence, the future scope of the spice extract-based ALT would be to test it with other pathogenic species of yeasts and bacteria. *In vivo* studies in the future will also help in customizing solutions for the elimination of cells within EPS gels and thereby avoiding catheter related infections. The ALT method developed, is rapid, affordable, easily adaptable and scalable in worldwide communities. The study offers a viable basis for developing and creating natural *in situ* ALT treatment options with aqueous garlic extract, either alone or as a robust combinatorial and synergistic design to treat drug-resistant indwelling catheter associated *Candida* biofilm infections.

5. Materials and Methods

5.1. Yeast Cultures

The clinical isolates of *C. albicans* M207 & S470 were used in the study. *C. albicans* M207 was isolated from the umbilical vein catheter of a female baby, and *C. albicans* S470 was isolated from the sputum of a female patient. Both the patients were affected with invasive Candidiasis. The cultures

were kindly provided by the Microbiology Laboratory, M S Ramaiah Medical College and Teaching Hospital, Bengaluru, Karnataka, India.

Ethical clearance was not required as no human subjects were involved in the study.

5.2. Growth Conditions

C. albicans M207 and S470 were sub-cultured on Trypticase Soy Agar (TSA) medium and incubated at 32°C for 24 h. The clinical isolates were stored as glycerol stocks (15% v/v) at -20°C for short-time experiments, however, the mother cultures were stored at -86°C.

5.3. Catheter

A silicone-based Foley's catheter (FC) (RUSCH) was used for the study. The cultures were grown in the lumen of the catheter for the induction of biofilm and to test the antifungal lock therapy.

5.4. Extract Preparation

The shelled garlic bulbs, fresh pitted Indian gooseberry fruit (amla) and whole clove buds were carefully chosen for the study as they are known to have antimicrobial properties. These three natural sources were chosen as our previous studies have demonstrated that aqueous garlic extract can effectively control biofilms of *C. albicans* M207 and *C. albicans* S470 and clove and Indian gooseberry can also control the latter [27,47]. Garlic, clove, and Indian gooseberry were locally sourced and authenticated by the Pharmacognosy Department, The Himalaya Drug Company, Makali, Bengaluru. Initially, the samples were washed in tap water followed by sterile water and air-dried before extraction. A weight of 10 g each of shelled garlic cloves and pitted gooseberry fruit were crushed in a pestle and mortar with 5 mL of sterile water, whereas a weight of 5 g of powdered clove was dissolved in 10 mL of sterile water. The extracts were centrifuged at 1000 rpm for 10 min at 4°C. The supernatant was filtered through Whatman filter paper and was used for further studies [27]. The crude extracts have been characterized and active principles have been detected via LCMS analysis in our previous study [47].

5.5. Pre-Inoculum

A loopful of *C. albicans* M207 and S470 were inoculated separately in test tubes with 5 mL of TSB medium, sealed and incubated overnight in a shaker incubator at 32°C. The next day, the optical density was read and the culture inoculum were adjusted to a cell count of 1×10^6 cells/mL for further experiments.

5.6. In Vitro Induction of *Candida albicans* Biofilm in Foley's Catheter and Spice Extract Based Antifungal Lock Therapy (ALT)

Pre-inoculated cultures were adjusted to a cell density of 1×10^6 cells/mL. The extracts of garlic (200 mg dry weight), clove (43 mg dry weight), and Indian gooseberry (86 mg dry weight), were prepared and kept ready. The *in vitro* ALT was applied by mixing the culture and the extract in a ratio of 1:1 along with a control plate in parallel. *C. albicans* M207 was treated with garlic extract and *C. albicans* S470 was treated with garlic, gooseberry and clove extracts individually. Foley's catheter tube was cut into 10 cm long pieces. One end of the catheter was sealed with parafilm, and the culture-spice extract mixture was added into the catheter from the other end and sealed with parafilm. The catheter was then incubated in an incubator at 32°C for 24 h. The next day the culture was removed from the catheter and washed with Phosphate Buffered Saline (PBS). Using a sterile blade, thin sections of the catheter was cut at the centre and periphery regions and used for further experimentation.

5.7. Point Inoculation

Thin sections of the catheter cut from the centre and periphery region of the catheter were placed at the centre of TSA plates and incubated for 16 h at 32°C. The growth of the culture biofilm was observed the following day.

5.8. MTT Assay

Thin sections of the centre and periphery regions of the catheters with 12 and 24 h grown cultures were placed in a 96-well microtiter plate. MTT (5 mg/mL) solution was added to each of the wells and incubated for 3 h. After the incubation period, MTT was discarded and acidified isopropanol was added to each well and incubated for 20 min. The wells were vigorously mixed and thereafter 100 µL aliquot was transferred to a fresh well and the absorbance was read at 540 nm using a microplate reader (Synergy HT, BioTek).

5.9. Colony-Forming Unit (CFU)

The catheter sections were added into Eppendorf tubes with 1 mL PBS each. With vigorous mixing the cells from the catheter sections were detached into the PBS solution. Serial dilution of the control and treated samples was done. The serially diluted samples were evenly spread on TSA plates by spread plate method and incubated at 32°C for 24 h. After incubation the colonies were counted and the CFU was calculated.

$$\text{CFU/mL} = \text{No. of colonies} \times \text{Dilution factor} / \text{Volume of culture plated} \quad \text{Eq 1}$$

5.10. Scanning Electron Microscopy

After the incubation periods of 12 and 24 h, the lumen of the catheter was washed with PBS and the catheter was sliced vertically and horizontally to get longitudinal section (LS) and cross section (CS). The LS and CS were then dipped in a 4% glutaraldehyde fixative for 1 h followed by a PBS wash. They were further dehydrated in a series of ethanol washes and later air-dried and stored for further studies [47]. The sections were mounted on a SEM stub and sputtered with gold. The images were captured at 2500X magnification using a JSM-IT300 scanning electron microscope at AFMM, Indian Institute of Science, Bengaluru, India.

5.11. Statistical Analysis

Three independent trials were performed for all the experiments. Values of broth microdilution were expressed as mean \pm standard deviation. The treated samples were compared with their respective controls. Statistical analysis was conducted by two-way ANOVA with p value of ≤ 0.05 which was statistically significant.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org. Figure S1: CFU of (A) *C. albicans* M207 control treated with (B) garlic extract at 12 h of incubation. (a) 10^{-2} , (b) 10^{-3} , (c) 10^{-4} dilutions. Figure S2: CFU of (A) *C. albicans* M207 control treated with (B) garlic extract at 24 h of incubation. (a) 10^{-2} , (b) 10^{-3} , (c) 10^{-4} dilutions. Figure S3: CFU of (A) *C. albicans* S470 control treated with (B) garlic, (C) gooseberry, and (D) clove extracts at 12 h of incubation. (a) 10^{-2} , (b) 10^{-3} , (c) 10^{-4} dilutions. Figure S4: CFU of (A) *C. albicans* S470 control treated with (B) garlic, (C) gooseberry, and (D) clove extracts at 24 h of incubation. (a) 10^{-2} , (b) 10^{-3} , (c) 10^{-4} dilutions. Figure S5: SEM analysis of cross section of catheter for (A) *C. albicans* M207 and (B) *C. albicans* S470 at 12 h. (a) Control, (b) Garlic treated, (c) Gooseberry Treated, (d) Clove treated. Figure S6: SEM analysis of cross section of catheter for (A) Blank, (B) *C. albicans* M207 and (C) *C. albicans* S470 at 24 h. (a) Control, (b) Garlic treated, (c) Gooseberry Treated, (d) Clove treated.

Author Contributions: Conceptualization, B.S.; methodology, B.S.; validation, B.S.; formal analysis, B.S., K.S.; investigation, B.S., V.V., A.R., H.S., M.G., N.K.K.N., N.M.D.; resources, B.S.; data curation, B.S., V.V., K.S.; writing—original draft preparation, V.V.; writing—review and editing, B.S., V.V., K.S.; visualization, B.S.; supervision, B.S.; project administration, B.S.; funding acquisition, B.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by THE KARNATAKA STATE COUNCIL FOR SCIENCE AND TECHNOLOGY (KSCST), grant number 7.1.01/SPP/10.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The original contributions presented in this study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author(s).

Acknowledgments: The authors wish to thank Dr. Beena, Dr. Rameez Raja, and Dr. Indumathi from Microbiology Lab at Ramaiah Teaching Hospital, Bengaluru for providing us with the *C. albicans* clinical isolates.

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Sikora, A.; Zahra, F. Nosocomial Infections. *StatPearls* **2023**.
2. D’Incau, S.; Atkinson, A.; Leitner, L.; Kronenberg, A.; Kessler, T.M.; Marschall, J. Bacterial Species and Antimicrobial Resistance Differ between Catheter and Non-Catheter-Associated Urinary Tract Infections: Data from a National Surveillance Network. *Antimicrob. Steward. Healthc. Epidemiol.* **2023**, *3*, e55, doi:10.1017/ASH.2022.340.
3. Venkataraman, R.; Yadav, U. Catheter-Associated Urinary Tract Infection: An Overview. *J. Basic Clin. Physiol. Pharmacol.* **2023**, *34*, 5–10, doi:10.1515/JBCPP-2022-0152/MACHINEREADABLECITATION/RIS.
4. Rubi, H.; Mudey, G.; Kunjalwar, R. Catheter-Associated Urinary Tract Infection (CAUTI). *Cureus* **2022**, *14*, doi:10.7759/CUREUS.30385.
5. Majumder, M.M.I.; Ahmed, T.; Ahmed, S.; Khan, A.R.; Majumder, M.M.I.; Ahmed, T.; Ahmed, S.; Khan, A.R. Microbiology of Catheter Associated Urinary Tract Infection. *Microbiol. Urin. Tract Infect. - Microb. Agents Predisposing Factors* **2018**, doi:10.5772/INTECHOPEN.80080.
6. Singhal, esha; Singh, R.; Bhardwaj, prashant; Kumari, M. Candida Species in Catheter Associated Urinary Tract Infection in ICU Patients at a Tertiary Care Hospital in North India: An Observational Study. *J. Med. Sci. Res. Orig. Res.* **2024**, *12*, 11–15, doi:10.17727/JMSR.2024/12-2.
7. TOSUN TAŞAR, P.; Karasahin, O.; Karahan, B.; Kiziltunc, S.; ALBAYRAK, A. Candidemia in Older Adults: What Are the Risk Factors for Mortality? *FLORA INFEKSIYON Hast. VE Klin. MIKROBIYOLOJİ Derg.* **2022**, *27*, 261–267, doi:10.5578/FLORA.20229809.
8. Porto, A.P.M.; Borges, I.C.; Buss, L.; Machado, A.; Bassetti, B.R.; Cocentino, B.; Bicalho, C.S.; Carrilho, C.M.D.M.; Rodrigues, C.; Neto, E.A.S.; et al. Healthcare-Associated Infections on the Intensive Care Unit in 21 Brazilian Hospitals during the Early Months of the Coronavirus Disease 2019 (COVID-19) Pandemic: An Ecological Study. *Infect. Control Hosp. Epidemiol.* **2023**, *44*, 284–290, doi:10.1017/ICE.2022.65.
9. Jain, M.; Dogra, V.; Mishra, B.; Thakur, A.; Loomba, S.L.; Bhargava, A. Candiduria in Catheterized Intensive Care Unit Patients: Emerging Microbiological Trends. *Indian J. Pathol. Microbiol.* **2011**, *54*, 552–555, doi:10.4103/0377-4929.85091.
10. Obaid, N.A.; Almarzoky Abuhussain, S.; Mulibari, K.K.; Alshantqi, F.; Malibari, S.A.; Althobaiti, S.S.; Alansari, M.; Muneef, E.; Almatrafi, L.; Alqarzi, A.; et al. Antimicrobial-Resistant Pathogens Related to Catheter-Associated Urinary Tract Infections in Intensive Care Units: A Multi-Center Retrospective Study in the Western Region of Saudi Arabia. *Clin. Epidemiol. Glob. Heal.* **2023**, *21*, 101291, doi:10.1016/J.CEGH.2023.101291.
11. Singh, Y.; Karicheri, R.; Nath, & Singh, Y.; Karicheri, R.; Nath, D. The Burden of Catheter Associated Urinary Tract Infection by Candida Albicans and Non Albicans with Emphasis on Biofilm Formation and Antifungal Sensitivity Pattern. *Int. J. Health Sci. (Qassim)*. **2022**, *6*, 2356–2363, doi:10.53730/IJHS.V6NS2.5544.
12. Mishra, N.; Kumari, D.; Mishra, A. Prevalence of Candida Species in Urinary Tract Infections from a Tertiary Care Hospital at Lucknow, Uttar Pradesh, India: A Retrospective Study. *Natl. J. Lab. Med.* **2022**, *15*, 27–32. doi:10.7860/NJLM/2022/56319.2676.
13. Al-Berfkani, M.I.; Allu, M.A.; Mousa, S.A. The Effect of Climate Temperature and Daily Water Intake on the Diversity of Uropathogens Causing Urinary Tract Infections in Adult Hospital Patients. *Diyala J. Med.* **2016**, *11*, 62–69.
14. Ionescu, A.C.; Brambilla, E.; Sighinolfi, M.C.; Mattina, R. A New Urinary Catheter Design Reduces In-Vitro Biofilm Formation by Influencing Hydrodynamics. **2021**, *114*, 153–162, doi:10.1016/J.JHIN.2021.01.033.
15. Sun, M.; Geng, H.; Bai, J.; Feng, J.; Xu, N.; Liu, Y.; Liu, X.; Liu, G. Characterization of Cervical Canal and Vaginal Bacteria in Pregnant Women with Cervical Incompetence. *Front. Microbiol.* **2022**, *13*, 986326, doi:10.3389/FMICB.2022.986326/BIBTEX.
16. Slate, A.J.; Clarke, O.E.; Kerio, M.; Nzakizwanayo, J.; Patel, B.A.; Jones, B. V. Infection Responsive Coatings to Reduce Biofilm Formation and Encrustation of Urinary Catheters. *J. Appl. Microbiol.* **2023**, *134*, 1–9, doi:10.1093/JAMBIO/LXAD121.

17. Singh, Y.; Karicheri, R.; Nath, & Singh, Y.; Karicheri, R.; Nath, D. How to Cite: The Burden of Catheter Associated Urinary Tract Infection by *Candida Albicans* and Non *Albicans* with Emphasis on Biofilm Formation and Antifungal Sensitivity Pattern. *Int. J. Health Sci. (Qassim)*. **2022**, *6*, 2356–2363, doi:10.53730/ijhs.v6nS2.5544.
18. Nguyen, T.T.; Palmer, S.C.; Cho, Y.; Mudge, D.W.; Strippoli, G.F.M.; Craig, J.C.; Johnson, D.W.; Htay, H. Peritoneal Dialysis. *Evidence-Based Nephrol. Second Ed.* **2022**, *2*, 138–155, doi:10.1002/9781119105954.CH48.
19. Tresso, K.A.; Santos, B.N. dos; Braga, F.T.M.M.; Margatho, A.S.; Mendes, K.D.S.; Silveira, R.C. de C.P. Lock Therapy in Prevention and Treatment of Catheter-Associated Bloodstream Infection: Integrative Review. *Acta Paul. Enferm.* **2023**, *36*, eAPE01221, doi:10.37689/ACTA-APE/2023AR012211.
20. Fakhim, H.; Vaezi, A.; Morovati, H.; Bandegani, A.; Abbasi, K.; Emami, S.; Nasiry, D.; Hashemi, S.M.; Ahangarkani, F.; Badali, H. In-Vivo Efficiency of the Novel Azole Compounds (ATTAF-1 and ATTAF-2) against Systemic Candidiasis in a Murine Model. *J. Med. Mycol.* **2023**, *33*, 101437, doi:10.1016/J.MYCMED.2023.101437.
21. Petraitiene, R.; Petraitis, V.; Zaw, M.H.; Hussain, K.; Ricart Arbona, R.J.; Roilides, E.; Walsh, T.J. Combination of Systemic and Lock-Therapies with Micafungin Eradicate Catheter-Based Biofilms and Infections Caused by *Candida Albicans* and *Candida Parapsilosis* in Neutropenic Rabbit Models. *J. Fungi* **2024**, *10*, 293, doi:10.3390/JOF10040293.
22. van der Sluijs, A. van E.; Eekelschot, K.Z.A.J.; Frakking, F.N.J.; Haas, P.J.A.; Boer, W.H.; Abrahams, A.C. Salvage of the Peritoneal Dialysis Catheter in *Candida* Peritonitis Using Amphotericin B Catheter Lock. *Perit. Dial. Int.* **2021**, *41*, 110–114, doi:10.1177/0896860820923238.
23. Mullins, C.; Beaulac, K.; Sylvia, L. Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment. *Annals of Pharmacotherapy* **2019**, *54*, 526–532, doi:10.1177/1060028019892587.
24. Kovács, R.; Majoros, L. Antifungal Lock Therapy: An Eternal Promise or an Effective Alternative Therapeutic Approach? *Lett. Appl. Microbiol.* **2022**, *74*, 851–862, doi:10.1111/LAM.13653.
25. Wunnoo, S.; Paosen, S.; Lethongkam, S.; Sukkurud, R.; Waen-ngoan, T.; Nuidate, T.; Phengmak, M.; Voravuthikunchai, S.P. Biologically Rapid Synthesized Silver Nanoparticles from Aqueous *Eucalyptus Camaldulensis* Leaf Extract: Effects on Hyphal Growth, Hydrolytic Enzymes, and Biofilm Formation in *Candida Albicans*. *Biotechnol. Bioeng.* **2021**, *118*, 1578–1592, doi:10.1002/BIT.27675.
26. Li, W.R.; Shi, Q.S.; Dai, H.Q.; Liang, Q.; Xie, X.B.; Huang, X.M.; Zhao, G.Z.; Zhang, L.X. Antifungal Activity, Kinetics and Molecular Mechanism of Action of Garlic Oil against *Candida Albicans*. *Sci. Rep* **2016**, *6*, 22805. doi: 10.1038/srep22805.
27. Ashrit, P.; Sadanandan, B.; Shetty, K.; Vaniyamparabath, V. Polymicrobial Biofilm Dynamics of Multidrug-Resistant *Candida Albicans* and Ampicillin-Resistant *Escherichia Coli* and Antimicrobial Inhibition by Aqueous Garlic Extract. *Antibiotics* **2022**, *11*, 573. doi: 10.3390/antibiotics11050573.
28. El-Baz, A.M.; Mosbah, R.A.; Goda, R.M.; Mansour, B.; Sultana, T.; Dahms, T.E.S.; El-Ganiny, A.M. Back to Nature: Combating *Candida Albicans* Biofilm, Phospholipase and Hemolysin Using Plant Essential Oils. *Antibiotics* **2021**, *10*, 81, doi:10.3390/ANTIBIOTICS10010081.
29. Sadanandan B, Prerna L, Humtsoe H, M.A. Antibacterial Activity of Garlic against *Bacillus Subtilis*. *Int. Rev. Appl. Biotechnol. Biochem* **2014**, *2*, 107–119.
30. Kumar, G.; Madka, V.; Pathuri, G.; Ganta, V.; Rao, C. V. Molecular Mechanisms of Cancer Prevention by Gooseberry (*Phyllanthus Emblica*). *Nutr. Cancer* **2022**, *74*, 2291–2302, doi:10.1080/01635581.2021.2008988.
31. Oosthuizen, C.B.; Reid, A.M.; Lall, N. Garlic (*Allium Sativum*) and Its Associated Molecules, as Medicine. *Med. Plants Holist. Heal. Well-Being* **2018**, 277–295, doi:10.1016/B978-0-12-812475-8.00009-3.
32. Tavares, L.; Santos, L.; Zapata Noreña, C.P. Bioactive Compounds of Garlic: A Comprehensive Review of Encapsulation Technologies, Characterization of the Encapsulated Garlic Compounds and Their Industrial Applicability. *Trends Food Sci. Technol.* **2021**, *114*, 232–244, doi:10.1016/J.TIFS.2021.05.019.
33. Rouf, R.; Uddin, S.J.; Sarker, D.K.; Islam, M.T.; Ali, E.S.; Shilpi, J.A.; Nahar, L.; Tiralongo, E.; Sarker, S.D. Antiviral Potential of Garlic (*Allium Sativum*) and Its Organosulfur Compounds: A Systematic Update of Pre-Clinical and Clinical Data. *Trends Food Sci. Technol.* **2020**, *104*, 219–234, doi:10.1016/J.TIFS.2020.08.006.
34. Pandey, V.K.; Srivastava, S.; Ashish; Dash, K.K.; Singh, R.; Dar, A.H.; Singh, T.; Farooqui, A.; Shaikh, A.M.; Kovacs, B. Bioactive Properties of Clove (*Syzygium Aromaticum*) Essential Oil Nanoemulsion: A Comprehensive Review. *Heliyon* **2024**, *10*, e22437, doi:10.1016/J.HELIVON.2023.E22437.
35. Moradi, E.; Rakhshandeh, H.; Rahimi Baradaran, V.; Ghadiri, M.; Hasanpour, M.; Iranshahi, M.; Askari, V.R. HPLC/MS Characterization of *Syzygium Aromaticum* L. and Evaluation of Its Effects on Peritoneal Adhesion: Investigating the Role of Inflammatory Cytokines, Oxidative Factors, and Fibrosis and Angiogenesis Biomarkers. *Physiol. Rep.* **2023**, *11*, e15584, doi:10.14814/PHY2.15584.
36. Haleema Shahin, D.H.; Sultana, R.; Farooq, J.; Taj, T.; Khaizer, U.F.; Alanazi, N.S.A.; Alshammari, M.K.; Alshammari, M.N.; Alsubaie, F.H.; Asdaq, S.M.B.; et al. Insights into the Uses of Traditional Plants for Diabetes Nephropathy: A Review. *Curr. Issues Mol. Biol.* **2022**, *44*, 2887–2902, doi:10.3390/CIMB44070199.
37. Prananda, A.T.; Dalimunthe, A.; Harahap, U.; Simanjuntak, Y.; Peronika, E.; Karosekali, N.E.; Hasibuan, P.A.Z.; Syahputra, R.A.; Situmorang, P.C.; Nurkolis, F. *Phyllanthus Emblica*: A Comprehensive Review of

- Its Phytochemical Composition and Pharmacological Properties. *Front. Pharmacol.* **2023**, *14*, 1288618, doi:10.3389/FPHAR.2023.1288618.
38. Gomez, S.; Anjali, C.; Kuruvila, B.; Maneesha, P.K.; Joseph, M. Phytochemical Constitution and Antioxidant Activity of Functional Herbal Drink from Indian Gooseberry (*Emblica Officinalis* Gaertn.) Fruits Containing Spices and Condiments. *Food Prod. Process. Nutr.* **2023**, *5*, 1–13, doi:10.1186/S43014-022-00127-8.
 39. Saini, R.; Sharma, N.; Oladeji, O.S.; Sourirajan, A.; Dev, K.; Zengin, G.; El-Shazly, M.; Kumar, V. Traditional Uses, Bioactive Composition, Pharmacology, and Toxicology of *Phyllanthus Emblica* Fruits: A Comprehensive Review. *J. Ethnopharmacol.* **2022**, *282*, 114570, doi:10.1016/J.JEP.2021.114570.
 40. Boonpisuttinant, K.; Ruksiriwanich, W.; Chutoprapat, R.; Udompong, S.; Kansawang, R.; Sangsee, J.; Chompoo, W.; Samothai, K.; Srisut, R. Assessment of in Vitro Anti-Skin Ageing Activities of Giant Indian Gooseberry (*Phyllanthus Indofischeri* Bennet) Extracts for Dermatological Health and Aesthetic Applications. **2023**, doi:10.21203/RS.3.RS-2891995/V1.
 41. Feneley, R.C.L.; Hopley, I.B.; Wells, P.N.T. Urinary Catheters: History, Current Status, Adverse Events and Research Agenda. *J. Med. Eng. Technol.* **2015**, *39*, 459–470, doi:10.3109/03091902.2015.1085600.
 42. Farrag, H.A.; El, A.; Ali, H.; Farrag, H.A.; El-Dien, A.; Hosny, M.S.; Hagra, S.A.A. Elimination and Prevention of Microbial Colonization of Central Venous Catheters Using Antibiotic Lock Technique and NonLeachable Form of Catheter Surface Incorporated Antibiotic b Elimination and Prevention of Microbial Colonization of Central Venous Catheters Using Antibiotic Lock Technique and Non-Leachable Form of Catheter Surface Incorporated Antibiotic by Gamma Radiation. *Artic. IOSR J. Pharm. Biol. Sci.* **2014**, *9*, 28–37, doi:10.9790/3008-09152833.
 43. Freire, M.P.; Pierrotti, L.C.; Zerati, A.E.; Benites, L.; Da Motta-Leal Filho, J.M.; Ibrahim, K.Y.; Araujo, P.H.; Abdala, E. Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria. *Antimicrob. Agents Chemother.* **2018**, *62*, 10-1128, doi:10.1128/AAC.00569-18.
 44. Ko, K.S.; Lee, J.Y.; Song, J.H.; Peck, K.R. In Vitro Evaluation of Antibiotic Lock Technique for the Treatment of *Candida Albicans*, *C. Glabrata*, and *C. Tropicalis* Biofilms. *J. Korean Med. Sci.* **2010**, *25*, 1722–1726, doi:10.3346/JKMS.2010.25.12.1722.
 45. Kovács, R.; Nagy, F.; Tóth, Z.; Bozó, A.; Balázs, B.; Majoros, L. Synergistic Effect of Nikkomycin Z with Caspofungin and Micafungin against *Candida Albicans* and *Candida Parapsilosis* Biofilms. *Lett. Appl. Microbiol.* **2019**, *69*, 271–278, doi:10.1111/LAM.13204.
 46. Öncü, S. In Vitro Effectiveness of Antifungal Lock Solutions on Catheters Infected with *Candida* Species. *J. Infect. Chemother.* **2011**, *17*, 634–639, doi:10.1007/S10156-011-0224-3.
 47. Sadanandan, B.; Vijayalakshmi, V.; Ashrit, P.; Babu, U.V.; Kumar, L.M.S.; Sampath, V.; Shetty, K.; Joglekar, A.P.; Awaknavar, R. Aqueous Spice Extracts as Alternative Antimycotics to Control Highly Drug Resistant Extensive Biofilm Forming Clinical Isolates of *Candida Albicans*. *PLoS One* **2023**, *18*, e0281035, doi:10.1371/JOURNAL.PONE.0281035.
 48. Dabur, R.; Gupta, A.; Mandal, T.K.; Singh, D.D.; Bajpai, V.; Gurav, A.M.; Lavekar, G.S. Antimicrobial Activity of Some Indian Medicinal Plants. *African J. Tradit. Complement. Altern. Med.* **2007**, *4*, 313, doi:10.4314/AJTAM.V4I3.31225.
 49. Sampaio, A. da G.; Gontijo, A.V.L.; Lima, G. de M.G.; de Oliveira, M.A.C.; Lepesqueur, L.S.S.; Koga-Ito, C.Y. Ellagic Acid–Cyclodextrin Complexes for the Treatment of Oral Candidiasis. *Mol.* **2021**, *26*, 505, doi:10.3390/MOLECULES26020505.
 50. Khounganian, R.M.; Alwakeel, A.; Albadah, A.; Nakshabandi, A.; Alharbi, S.; Almslam, A.S. The Antifungal Efficacy of Pure Garlic, Onion, and Lemon Extracts Against *Candida Albicans*. *Cureus* **2023**, *15*, e38637, doi:10.7759/CUREUS.38637.
 51. Biernasiuk, A.; Baj, T.; Malm, A. Clove Essential Oil and Its Main Constituent, Eugenol, as Potential Natural Antifungals against *Candida* Spp. Alone or in Combination with Other Antimycotics Due to Synergistic Interactions. *Molecules* **2023**, *28*, 215, doi:10.3390/MOLECULES28010215/S1.
 52. Rajkowska, K.; Otlewska, A.; Kunicka-Styczyńska, A.; Krajewska, A. *Candida Albicans* Impairments Induced by Peppermint and Clove Oils at Sub-Inhibitory Concentrations. *Int. J. Mol. Sci.* **2017**, *18*, 1307, doi:10.3390/IJMS18061307.
 53. Khurana, S.K.; Tiwari, R.; Sharun, K.; Iqbal Yattoo, M.; Gugjoo, M.B.; Dhama, K. *Emblica Officinalis* (Amla) with a Particular Focus on Its Antimicrobial Potentials: A Review. *J. Pure Appl. Microbiol.* **2019**, *13*, 1995–2012, doi:10.22207/JPAM.13.4.11.
 54. Tsegay, Z.T.; Mulaw, G. Antimicrobial Activities and Mode of Action of Bioactive Substances from Vegetable and Fruit Byproducts as a Current Option for Valorization. *Waste Biomass Valorization* **2024**, 1–28, doi:10.1007/S12649-024-02587-0.
 55. Sahidur, M.R.; Islam, S.; Jahurul, M.H.A. Garlic (*Allium Sativum*) as a Natural Antidote or a Protective Agent against Diseases and Toxicities: A Critical Review. *Food Chem. Adv.* **2023**, *3*, 100353, doi:10.1016/J.FOCHA.2023.100353.
 56. Didehdar, M.; Chegini, Z.; Shariati, A. Eugenol: A Novel Therapeutic Agent for the Inhibition of *Candida* Species Infection. *Front. Pharmacol.* **2022**, *13*, 872127, doi:10.3389/FPHAR.2022.872127/BIBTEX.

57. Ferreira, J.A.G.; Carr, J.H.; Starling, C.E.F.; De Resende, M.A.; Donlan, R.M. Biofilm Formation and Effect of Caspofungin on Biofilm Structure of Candida Species Bloodstream Isolates. *Antimicrob. Agents Chemother.* **2009**, *53*, 4377, doi:10.1128/AAC.00316-09.
58. Sieuwerts, S.; De Bok, F.A.M.; Mols, E.; De Vos, W.M.; Van Hylckama Vlieg, J.E.T. A Simple and Fast Method for Determining Colony Forming Units. *Lett. Appl. Microbiol.* **2008**, *47*, 275–278, doi:10.1111/J.1472-765X.2008.02417.X.
59. LaFleur, M.D.; Kumamoto, C.A.; Lewis, K. Candida Albicans Biofilms Produce Antifungal-Tolerant Persister Cells. *Antimicrob. Agents Chemother.* **2006**, *50*, 3839–3846, doi:10.1128/AAC.00684-06.
60. Mukherjee, P.K.; Long, L.; Kim, H.G.; Ghannoum, M.A. Amphotericin B Lipid Complex Is Efficacious in the Treatment of Candida Albicans Biofilms Using a Model of Catheter-Associated Candida Biofilms. *Int. J. Antimicrob. Agents* **2009**, *33*, 149–153, doi:10.1016/J.IJANTIMICAG.2008.07.030.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.